In contrast, BTN3A1 expression was significantly lower in breast cancer (BRCA), kidney chromophobe (KICH), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), prostate adenocarcinoma (PRAD), and uterine corpus endometrial carcinoma (UCEC), in comparison with that in counterpart normal tissue controls (Fig. 1A). This evidence concerns the gene BTN3A1 and uterine corpus endometrial carcinoma.